CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
06 mai 2022 19h30 HE
|
Gritstone bio
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines...
Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
05 mai 2022 16h05 HE
|
Gritstone bio
-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines...
Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders
02 mai 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27 avr. 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery
12 avr. 2022 16h35 HE
|
Gritstone bio
-- Translational immunology data and cassette design capabilities enabled development of an optimized, KRAS-specific version of “off-the-shelf” vaccine candidate now in Phase 2 (SLATE-KRAS) -- --...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 mars 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate Updates
10 mars 2022 16h05 HE
|
Gritstone bio
-- Four trials now initiated for CORAL, Gritstone’s second-generation COVID-19 program focused on delivering T cell enhanced self-amplifying mRNA (samRNA) vaccines -- -- Oncology programs advancing...
Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual Meeting
08 mars 2022 17h15 HE
|
Gritstone bio
-- Oral presentation to discuss how translational immunology data enabled iterative development of an optimized, KRAS-specific version of “off-the shelf” vaccine candidate; the optimized...
Gritstone to Participate in Cowen 42nd Annual Health Care Conference
24 févr. 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 févr. 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...